08048035996
Mounjaro 10 mg Injection affordable injection to USA - Los Angeles | Phoenix Exim | Trusted Exporter

1. General Information

Mounjaro 10 mg Prefilled Pen contains tirzepatide, a prescription injectable medicine belonging to the dual GIP and GLP-1 receptor agonist class. It is administered once weekly by subcutaneous injection and is primarily used to improve blood glucose control in adults with type 2 diabetes mellitus, together with diet and exercise.

Mounjaro is available in different strengths, and 10 mg is generally a maintenance dose rather than a starting dose. Treatment should be initiated and adjusted according to a healthcare professional's instructions.

Phoenix Exim is a pharmaceutical exporter based in Nagpur, India, serving international pharmaceutical buyers and markets including the USA, UK, Australia, Singapore, Canada, South Korea and UAE, subject to applicable import, prescription and regulatory requirements.


2. Product Information

ProductMounjaro 10 mg Prefilled Pen
Active IngredientTirzepatide
Strength10 mg
Dosage FormInjectable solution
AdministrationSubcutaneous injection
FrequencyOnce weekly
Drug ClassGIP/GLP-1 receptor agonist
PrescriptionYes
Manufacturer/BrandMounjaro
StorageRefrigerated according to product labeling

The US prescribing information describes Mounjaro as a clear, colorless to slightly yellow sterile solution for subcutaneous use. The single-dose presentation contains 10 mg tirzepatide in 0.5 mL.


3. Uses of Mounjaro 10 mg

Mounjaro is used along with diet and exercise to help improve blood sugar control in adults with type 2 diabetes mellitus.

Tirzepatide may:

  • Help reduce blood glucose levels
  • Improve fasting and after-meal glucose control
  • Increase glucose-dependent insulin secretion
  • Reduce glucagon secretion
  • Reduce food intake
  • Support reduction in body weight in patients with type 2 diabetes

The exact indication and approved uses can differ between countries, so products should be supplied and used according to the regulations applicable in the destination market.


4. Benefits of Mounjaro 10 mg

Potential therapeutic benefits include:

  • Once-weekly dosing
  • Improved blood glucose control when used as prescribed
  • Dual GIP and GLP-1 receptor activity
  • Reduced food intake
  • Potential reduction in body weight
  • Convenient prefilled-pen delivery
  • Different dose strengths allow healthcare professionals to individualize treatment

Mounjaro's dual GIP/GLP-1 activity distinguishes tirzepatide from medicines that activate only the GLP-1 receptor.


5. Side Effects of Mounjaro 10 mg

Like other prescription medicines, Mounjaro can cause side effects. Gastrointestinal reactions are among the most frequently reported.

Possible adverse effects include:

  • Nausea
  • Diarrhea
  • Decreased appetite
  • Vomiting
  • Constipation
  • Abdominal discomfort or pain
  • Indigestion

More serious risks can occur, including severe gastrointestinal reactions, pancreatitis, gallbladder problems, dehydration-related kidney problems, hypoglycemia when combined with certain diabetes medicines, and serious allergic reactions.

Mounjaro also carries a boxed warning regarding thyroid C-cell tumors observed in rats. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).


6. Common Side Effects

Commonly reported side effects include:

  • Nausea
  • Diarrhea
  • Decreased appetite
  • Vomiting
  • Constipation
  • Dyspepsia
  • Abdominal pain

Gastrointestinal symptoms can be more noticeable during dose escalation and may decrease over time in some patients.

Patients should contact their healthcare professional if side effects are severe, persistent or concerning.


7. How to Use Mounjaro 10 mg Prefilled Pen

Mounjaro is administered once weekly by subcutaneous injection.

Typical administration sites include:

  • Abdomen
  • Thigh
  • Back of the upper arm when administered by another person

Patients should follow the injection instructions supplied with their specific pen presentation and their healthcare professional's directions. Do not inject Mounjaro into a vein or muscle.

For the current Mounjaro KwikPen presentation, each pen contains four fixed weekly doses. The manufacturer instructions state that the pen should not be shared and that leftover medicine should not be transferred to a syringe.

Important: Do not begin with 10 mg unless specifically prescribed. Dose escalation is normally performed gradually to improve tolerability.


8. How Mounjaro Works

Mounjaro contains tirzepatide, which activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors.

Its actions include:

  1. Increasing glucose-dependent insulin secretion.
  2. Reducing glucagon secretion.
  3. Slowing certain aspects of gastrointestinal motility.
  4. Reducing food intake.
  5. Improving glucose regulation.
  6. Supporting body-weight reduction in appropriate patients.

Tirzepatide's molecular structure also allows prolonged activity, supporting its once-weekly administration.


9. Safety Advice

Mounjaro should be used only under appropriate medical supervision.

Important safety points:

  • Use only the dose prescribed by a healthcare professional.
  • Do not use Mounjaro if you have a personal or family history of MTC or MEN 2.
  • Tell your doctor about all medicines you take, particularly insulin or sulfonylureas.
  • Report severe or persistent abdominal pain.
  • Seek medical attention for symptoms of a serious allergic reaction.
  • Maintain adequate hydration, particularly if vomiting or diarrhea occurs.
  • Do not share the injection pen with another person.
  • Do not use a pen that has been frozen.
  • Store the medicine according to the current product labeling.
  • Keep the medicine away from children.
  • Check the product packaging, storage conditions and expiry date before use.

The FDA labeling specifically instructs patients not to freeze the pen and provides temperature/storage requirements that should be followed for the applicable pen presentation.


10. Frequently Asked Questions (FAQs)

What is Mounjaro 10 mg?

Mounjaro 10 mg is a prescription injectable containing 10 mg of tirzepatide. It is administered once weekly and is used primarily for blood glucose control in adults with type 2 diabetes.

Is Mounjaro 10 mg a starting dose?

Generally, no. Mounjaro treatment is usually started at a lower dose and increased gradually according to the prescribing information and healthcare professional's advice.

How often is Mounjaro 10 mg taken?

It is administered once weekly.

Can Mounjaro be used for weight loss?

Tirzepatide has effects on appetite and body weight. However, the approved indication depends on the specific tirzepatide product and country. Patients should use the product only for an indication approved for that product in their jurisdiction.

Does Mounjaro require a prescription?

Yes. Mounjaro is a prescription medicine.

Where is Mounjaro injected?

It is injected under the skin, commonly in the abdomen or thigh. Another person may administer it in the back of the upper arm.

Can Mounjaro be shared?

No. The pen should never be shared with another person, even if the needle is changed.

How should Mounjaro be stored?

Storage requirements depend on the specific presentation and current labeling. Refrigeration is required for the standard US product, and the medicine should not be frozen.

Can I switch from another GLP-1 medicine to Mounjaro?

A healthcare professional should determine whether switching is appropriate and establish the correct dose and schedule.


11. Substitutes / Therapeutic Alternatives

There is no universal one-to-one substitute for Mounjaro. The appropriate alternative depends on the patient's diagnosis, treatment goals, medical history and country-specific approvals.

Possible medicines a healthcare professional may consider include:

  • Semaglutide – GLP-1 receptor agonist available in different products and indications.
  • Dulaglutide – GLP-1 receptor agonist used for type 2 diabetes.
  • Liraglutide – GLP-1 receptor agonist with approved uses that vary by product and country.
  • Other glucose-lowering medicines – selected according to the patient's individual treatment plan.

These medicines should not be substituted or switched without professional medical advice.


12. SEO Keywords

  1. Mounjaro 10 mg Prefilled Pen
  2. Mounjaro 10 mg injection
  3. Tirzepatide 10 mg injection
  4. Tirzepatide prefilled pen exporter
  5. Mounjaro pharmaceutical exporter India
  6. Mounjaro 10 mg supplier India
  7. Tirzepatide medicine exporter
  8. Mounjaro 10 mg wholesale supplier
  9. Mounjaro 10 mg pharmaceutical supply
  10. Tirzepatide injection supplier India
  11. Mounjaro 10 mg exporter from Nagpur
  12. Mounjaro 10 mg international pharmaceutical supplier
  13. Tirzepatide 10 mg prefilled injection
  14. Mounjaro 10 mg B2B pharmaceutical supplier
  15. Tirzepatide 10 mg wholesale export
  16. Mounjaro pen pharmaceutical distributor
  17. Mounjaro 10 mg global supply
  18. Tirzepatide injectable medicine supplier
  19. Mounjaro 10 mg pharma export India
  20. Prescription injectable medicine exporter India
  21. Tirzepatide 10 mg bulk pharmaceutical supply
  22. Mounjaro 10 mg medicine supplier
  23. Mounjaro pen export supplier
  24. Tirzepatide pharmaceutical products India
  25. Mounjaro 10 mg international supplier
  26. GIP GLP-1 receptor agonist supplier
  27. Tirzepatide injection pharmaceutical exporter
  28. Mounjaro 10 mg B2B supplier
  29. Pharmaceutical exporter from Nagpur India
  30. Tirzepatide 10 mg export supplier
Aug 11th, 2026 2:51 PM

Keywords